Program
upadacitinib
Also written as “Upadacitinib”, “ABT-494” and “Upadacitinib 15 MG [Rinvoq]”.
Its studies are mostly in Dermatitis, Atopic · Arthritis, Rheumatoid · Crohn Disease · Colitis, Ulcerative · Alopecia Areata, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVie | 6121 open or running | phase 4since Aug 18, 2022 | Dec 3, 2012 | Nov 2026phase 3 · NCT06389136 |
| CARE ARTHRITIS | 22 open or running | phase 4since Jun 6, 2024 | Jun 6, 2024 | May 2027phase 4 · NCT07018206 |
| Modern Biosciences | 11 open or running | phase 1since Apr 8, 2024 | Apr 8, 2024 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 47 studies since Feb 16, 2015.
- Apr 25, 20242 phase 3 studies in Dermatitis, AtopicAbbVie · NCT06389136, NCT06390722
- Jun 6, 2024CARE ARTHRITIS's first study: phase 4 study in Arthritis, PsoriaticNew to CARE ARTHRITISCARE ARTHRITIS · NCT06454188 · 100 planned · United States, Canada
- Jun 12, 2024Phase 3 study in Dermatitis, AtopicAbbVie · NCT06461897 · 699 enrolled · United States, Argentina, Australia and more
- Nov 21, 2024Phase 3 study in Dermatitis, AtopicAbbVie · NCT06701331 · 99 enrolled · Japan
- May 27, 2025Phase 4 study in Axial SpondyloarthritisCARE ARTHRITIS · NCT07018206 · 200 planned · United States
- Jun 10, 2025Phase 3 study in Alopecia AreataAbbVie · NCT07023302 · 125 enrolled · Japan
- Feb 17, 2026Phase 1 study in Healthy VolunteerAbbVie · NCT07425899 · 16 enrolled · United States
- Aug 11, 2026Phase 3 study in Alopecia AreataAbbVie · NCT07772492 · 300 planned · United States, Australia, Japan and more
- Sep 22, 2026Phase 1 study in Healthy VolunteersAbbVie · NCT07843693 · 60 planned · United States
- Oct 16, 2026Primary completion moved from 2027-06 to 2031-01Date moved laterphase 3 · +43 months · NCT06332534
- Oct 16, 2026Primary completion moved from 2026-08 to 2026-11Date moved laterphase 3 · +3 months · NCT06389136
- Oct 21, 20262 phase 3 studiesAbbVie · NCT07896434, NCT07933211
- Oct 23, 2026Phase 2 study in Arthritis, RheumatoidAbbVie · NCT07904754 · 250 planned
- Nov 13, 2026Primary completion moved from 2028-03 to 2028-08Date moved laterphase 3 · +5 months · NCT05889182
Ahead
- Nov 2026Primary completion: phase 3 study in Dermatitis, AtopicAbbVie · NCT06389136
- Dec 2026Primary completion: phase 1 study in Healthy VolunteersAbbVie · NCT07843693
- Jan 2027Primary completion: phase 3 study in Dermatitis, AtopicAbbVie · NCT06701331
- Mar 2027Primary completion: phase 3 study in Lupus Erythematosus, SystemicAbbVie · NCT05843643
TargetBeta
“Tyrosine-protein kinase TYK2 inhibitor; Tyrosine-protein kinase JAK3 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase JAK1 inhibitor”ChEMBL 37, by rule
Other programs on the same 4 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ruxolitinibrule | Incyte | phase 4 | 95 |
| tofacitinibrule | Pfizer | phase 4 | 94 |
| filgotinib maleaterule | Eisai | phase 4 | 2 |
| filgotinibrule | Lakefront Biotherapeutics NV | phase 3 | 46 |
| delgocitinibrule | LEO Pharma | phase 3 | 21 |
Studies
The newest 60 of 64 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07933211Scleroderma, Systemic | 3 | Not yet recruiting | AbbVie | Jun 2035 | 580 |
| NCT07904754Arthritis, Rheumatoid | 2 | Not yet recruiting | AbbVie | Jul 2029 | 250 |
| NCT07896434Non-Segmental Vitiligo | 3 | Not yet recruiting | AbbVie | Aug 2032 | 154 |
| NCT07843693Healthy Volunteers · United States | 1 | Recruiting | AbbVie | Dec 2026 | 60 |
| NCT07772492Alopecia Areata · United States, Australia, Japan and more | 3 | Recruiting | AbbVie | Mar 2032 | 300 |
| NCT07425899Healthy Volunteer · United States | 1 | Completed | AbbVie | Jun 5, 2026 | 16 |
| NCT07023302Alopecia Areata · Japan | 3 | Active, not recruiting | AbbVie | Feb 2029 | 125 |
| NCT07018206Axial Spondyloarthritis · United States | 4 | Not yet recruiting | CARE ARTHRITIS | May 2027 | 200 |
| NCT06701331Dermatitis, Atopic · Japan | 3 | Active, not recruiting | AbbVie | Jan 2027 | 99 |
| NCT06461897Dermatitis, Atopic · United States, Argentina, Australia and more | 3 | Active, not recruiting | AbbVie | Nov 2029 | 699 |
| NCT06454188Arthritis, Psoriatic · United States, Canada | 4 | Recruiting | CARE ARTHRITIS | Sep 2028 | 100 |
| NCT06390722Dermatitis, Atopic | 3 | Withdrawn | AbbVie | Jan 5, 2026 | 0 |
| NCT06389136Dermatitis, Atopic · United States, Canada, Colombia and more | 3 | Active, not recruiting | AbbVie | Nov 2026 | 184 |
| NCT06379958Pharmacokinetics · United Kingdom | 1 | Recruiting | Modern Biosciences | Sep 30, 2024 | 48 |
| NCT06332534Crohn Disease · United States, Australia, Belgium and more | 3 | Active, not recruiting | AbbVie | Jan 2031 | 111 |
| NCT06118411Vitiligo · United States, Argentina, Belgium and more | 3 | Active, not recruiting | AbbVie | Mar 2028 | 614 |
| NCT06012240Alopecia Areata · United States, Argentina, Australia and more | 3 | Recruiting | AbbVie | Apr 2030 | 1,500 |
| NCT05889182Hidradenitis Suppurativa · United States, Argentina, Australia and more | 3 | Active, not recruiting | AbbVie | Aug 2028 | 1,328 |
| NCT05843643Lupus Erythematosus, Systemic · United States, Argentina, Australia and more | 3 | Active, not recruiting | AbbVie | Mar 2027 | 1,014 |
| NCT05814627Arthritis, Rheumatoid · United States, Argentina, Belgium and more | 3 | Completed | AbbVie | Jul 15, 2026 | 487 |
| NCT05782907Colitis, Ulcerative · United States, Australia, Belgium and more | 3 | Active, not recruiting | AbbVie | Aug 2028 | 122 |
| NCT05609630Arthritis, Juvenile · United States, Argentina, Australia and more | 3 | Recruiting | AbbVie | Jun 2029 | 90 |
| NCT05601882Dermatitis, Atopic · United States, Australia, Belgium and more | 3 | Completed | AbbVie | Mar 19, 2024 | 920 |
| NCT05507580Dermatitis, Atopic · Australia, Belgium, Bulgaria and more | 4 | Completed | AbbVie | Jul 11, 2024 | 461 |
| NCT04927975Vitiligo · United States, Canada, France and more | 2 | Completed | AbbVie | Jan 13, 2023 | 185 |
| NCT04666675Dermatitis, Atopic | 3 | Withdrawn | AbbVie | Mar 23, 2021 | 0 |
| NCT04451772Lupus Erythematosus, Systemic · United States, Argentina, Australia and more | 2 | Completed | AbbVie | Jan 3, 2024 | 185 |
| NCT04430855Hidradenitis Suppurativa · United States, Canada, Japan and more | 2 | Completed | AbbVie | Apr 22, 2021 | 68 |
| NCT04195698Dermatitis, Atopic · United States, Australia, Canada and more | 3 | Completed | AbbVie | Sep 11, 2023 | 475 |
| NCT04169373Spondylarthritis · United States, Argentina, Australia and more | 3 | Completed | AbbVie | Sep 2, 2021 | 734 |
| NCT04161898Takayasu Arteritis · Argentina, Brazil, China and more | 3 | Active, not recruiting | AbbVie | Aug 2028 | 56 |
| NCT03978520Lupus Erythematosus, Systemic · United States, Argentina, Australia and more | 2 | Completed | AbbVie | Jan 19, 2022 | 341 |
| NCT03823378Arthritis, Rheumatoid · Belgium, Canada, Czechia and more | 2 | Terminated | AbbVie | Sep 9, 2020 | 97 |
| NCT03738397Dermatitis, Atopic · United States, Australia, Canada and more | 3 | Completed | AbbVie | Aug 27, 2020 | 673 |
| NCT03725202Giant Cell Arteritis · United States, Australia, Austria and more | 3 | Completed | AbbVie | Feb 6, 2024 | 429 |
| NCT03725007Arthritis, Juvenile · United States, Canada, Germany and more | 1 | Active, not recruiting | AbbVie | Dec 2028 | 124 |
| NCT03682705Arthritis, Rheumatoid · United States, Belgium, Canada and more | 2 | Completed | AbbVie | Mar 26, 2020 | 242 |
| NCT03661138Dermatitis, Atopic · Japan | 3 | Completed | AbbVie | Aug 19, 2022 | 272 |
| NCT03653026Colitis, Ulcerative · United States, Argentina, Australia and more | 3 | Completed | AbbVie | Jan 14, 2021 | 522 |
| NCT03646604Dermatitis, Atopic · United States, Norway, Puerto Rico | 1 | Completed | AbbVie | Aug 29, 2024 | 35 |
| NCT03607422Dermatitis, Atopic · United States, Australia, Austria and more | 3 | Completed | AbbVie | Mar 11, 2021 | 912 |
| NCT03569293Dermatitis, Atopic · United States, Argentina, Australia and more | 3 | Completed | AbbVie | Jan 6, 2021 | 912 |
| NCT03568318Dermatitis, Atopic · United States, Australia, Austria and more | 3 | Active, not recruiting | AbbVie | Feb 16, 2021 | 1,533 |
| NCT03345849Crohn Disease · United States, Argentina, Australia and more | 3 | Completed | AbbVie | Oct 15, 2021 | 526 |
| NCT03345836Crohn Disease · United States, Argentina, Australia and more | 3 | Completed | AbbVie | Aug 11, 2021 | 624 |
| NCT03345823Crohn Disease · United States, Argentina, Australia and more | 3 | Active, not recruiting | AbbVie | Sep 2027 | 747 |
| NCT03178487Spondylitis, Ankylosing · United States, Australia, Belgium and more | 2 | Completed | AbbVie | Jan 21, 2019 | 187 |
| NCT03104400Arthritis, Psoriatic · United States, Argentina, Australia and more | 3 | Completed | AbbVie | Sep 26, 2019 | 1,705 |
| NCT03104374Arthritis, Psoriatic · United States, Australia, Belgium and more | 3 | Completed | AbbVie | Jul 23, 2019 | 642 |
| NCT03006068Colitis, Ulcerative · United States, Argentina, Australia and more | 3 | Active, not recruiting | AbbVie | Jul 2027 | 950 |
| NCT02955212Arthritis, Rheumatoid · Brazil, China, Korea, Republic of | 3 | Completed | AbbVie | Aug 14, 2019 | 338 |
| NCT02925117Dermatitis, Atopic · United States, Australia, Canada and more | 2 | Completed | AbbVie | Aug 10, 2017 | 167 |
| NCT02819635Colitis, Ulcerative · United States, Argentina, Australia and more | 3 | Completed | AbbVie | Dec 13, 2021 | 1,302 |
| NCT02782663Crohn Disease · United States, Belgium, Canada and more | 2 | Completed | AbbVie | Jul 18, 2025 | 107 |
| NCT02720523Arthritis, Rheumatoid · Japan | 3 | Completed | AbbVie | Aug 3, 2017 | 197 |
| NCT02706951Arthritis, Rheumatoid · United States, Argentina, Australia and more | 3 | Completed | AbbVie | Oct 2, 2017 | 648 |
| NCT02706873Arthritis, Rheumatoid · United States, Argentina, Australia and more | 3 | Completed | AbbVie | Mar 15, 2018 | 1,002 |
| NCT02706847Arthritis, Rheumatoid · United States, Australia, Austria and more | 3 | Completed | AbbVie | Apr 3, 2017 | 499 |
| NCT02675426Arthritis, Rheumatoid · United States, Argentina, Australia and more | 3 | Completed | AbbVie | Apr 21, 2017 | 661 |
| NCT02365649Crohn Disease | 2 | Completed | AbbVie | Nov 25, 2016 | 220 |
How it is read
Names in the registry
- “Upadacitinib”, 54 entries
- “ABT-494”, 4 entries
- “Upadacitinib 15 MG [Rinvoq]”, 2 entries
- “Upadacitinib (ABT-494)”, 2 entries
- “Upadacitinib 15mg Dose”, 1 entry
Conditions, from the studies’ own filings
- Dermatitis, Atopic, 15 studies
- Arthritis, Rheumatoid, 14 studies
- Crohn Disease, 6 studies
- Colitis, Ulcerative, 4 studies
- Alopecia Areata, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.